Zenas Biopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
FMR LLC and Abigail P. Johnson have disclosed a 14.3% beneficial ownership stake in Zenas Biopharma Inc. common stock as of December 31, 2025.
NASDAQ
Novo Holdings A/S, a Danish investment firm, has disclosed a 4.7% beneficial ownership stake in Zenas BioPharma, Inc. common stock.
NASDAQ
InnoCare Pharma Inc. and its affiliates have reported a 9.4% beneficial ownership stake in Zenas BioPharma, Inc., totaling 5,000,000 shares of common stock.
NASDAQ
FMR LLC and Abigail P. Johnson have reported an 11.0% beneficial ownership stake in Zenas BioPharma Inc.'s common stock as of August 29, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson reported a 7.9% beneficial ownership stake in Zenas Biopharma Inc. as of June 30, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 6.8% of Zenas BioPharma Inc.'s common stock as of March 31, 2025.
NASDAQ
Novo Holdings A/S, a Danish investment firm, has reported a passive beneficial ownership of 5.3% in Zenas BioPharma, Inc., holding 2,214,967 shares of common stock.